Sign in Create account

Everest Organics Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524790
₹221.50
▼ -1.20 (-0.54%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
36/100
Weak
Valuation
39/100
Fairly Valued
Momentum
28/100
Bearish

QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹215 Cr
PE (TTM)
36.8
Industry median 36.1 (152 companies)
Price to Book
2.8
PEG (TTM)
2.2
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-23.5
Free Cash Flow
₹5 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-20.69%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
243.67%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
5.49%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-20.78%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-10.00%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.10
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.66
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
2.08
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
2.30%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
6.52%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
7.48%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
1.82%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
20.47%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
5.38%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (0.66)
  • No Return on equity is 15% or more (5.4%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.5%
Low 218.1000 · High 229.0000
1W return
-8.6%
Low 213.4500 · High 267.8500
1M return
-19.1%
Low 213.4500 · High 284.0000
52W return
-23.5%
Low 213.4500 · High 333.0000
Lifetime High ₹439.0500 (May 26, 2021)
Lifetime Low ₹12.5000 (March 11, 2016)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish2
Bearish4
5D
226.1
10D
234.8
20D
245.5
50D
235.8
100D
206.6
200D
159.7

Delivery and volume

Day avg. delivery
75.1%
Week avg. delivery
80.9%
Month avg. delivery
83.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

222.87
Pivot
First resistance227.63
Second resistance233.77
Third resistance238.53
First support216.73
Second support211.97
Third support205.83
Day RSI33.6
Day MFI25.3
Day MACD-9.17
Day MACD signal-3.39

Beta

1M0.94
3M0.49
1Y0.49
3Y0.78

Price change analysis

↓ -19.1%
Over 1 Month
LowHigh
213.45284.00
↓ -23.5%
Over 3 Months
LowHigh
213.45333.00
↓ -23.5%
Over 6 Months
LowHigh
213.45333.00
↓ -23.5%
Over 1 Year
LowHigh
213.45333.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 36.8 (own history: 45.8–675.3)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹48 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹1.1500

Ranks #115 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter59.60%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings increased from 59.58% to 59.60% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 3 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
13 Jun 2025 BK LEGACY TRUST Bulk Sell 55,824 402.5000 BSE
3 Apr 2025 JAY JANAK JESRANI Bulk Buy 49,414 270.0200 BSE
21 Aug 2019 MADRAS PARAMESWARAN MANOJ MAHADEV Bulk Buy 43,082 205.7300 BSE

All bulk and block deals →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 AGM/EGM Everest Organics Ltd - 524790 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 AGM/EGM Everest Organics Ltd - 524790 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 Insider Trading / SAST Everest Organics Ltd - 524790 - Closure of Trading Window
9 Sep 2026 Company Update Everest Organics Ltd - 524790 - Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Sep 2026 AGM/EGM Everest Organics Ltd - 524790 - Notice Of 33Rd Annual General Meeting And 33Rd Annual Report For The FY 2025-26
8 Sep 2026 Others Everest Organics Ltd - 524790 - Reg. 34 (1) Annual Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Low Return on Equity (5.4%)
  • Thin net profit margin (2.3%)
  • Declining revenue YoY (-10.0%)
  • Declining profit YoY (-20.8%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (36.8) -- priced for continued strong execution
  • Down 23.5% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Everest Organics Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.